Cancer therapeutic drug, method for assisting examination, and method for screening therapeutic drug
By inhibiting hSATII RNA and increasing CTCF expression, the cancer problem caused by high expression of non-translated RNA in senescent cells is solved, effective treatment and diagnosis of senescent cells and interstitial cells is achieved, and new cancer treatment and screening methods are provided. , improves treatment effect and early detection capabilities.
Patent Information
- Application Number
- CN202380029506.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-01
- Filing Date
- 2023-03-31
- Publication Date
- 2024-11-15
AI Technical Summary
The prior art is difficult to effectively inhibit the expression of highly expressed untranslated RNA (hSATII RNA) and CTCF in senescent cells, resulting in cancer worsening, and the lack of new target molecules related to cellular senescence for cancer treatment and diagnosis.
By inhibiting the expression of hSATII RNA or hindering its activity and increasing CTCF expression, therapeutic drugs targeting senescent cells and interstitial cells were developed in combination with chemotherapy or radiotherapy to induce cell death and by detecting the expression changes of hSATII RNA and CTCF Carry out cancer diagnosis and treatment drug screening.
It effectively inhibits cancers related to senescent cells, induces cancer cells and stromal cell death, prevents cancer recurrence, and provides methods for early detection and screening of new therapeutic drugs, improving the effectiveness of cancer treatment.
Smart Images

Figure CN118973612A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a drug for treating cancer by inhibiting the expression of inflammation-related genes and controlling cell survival by targeting non-translated RNA expressed in senescent cells, a method for examining cancer, and a method for screening therapeutic drugs. Background Art
[0002] Cancer is known to be caused by a variety of factors. One of them is "cellular senescence". Cellular senescence is a state in which the cell cycle is irreversibly stopped due to various stresses such as oxidative stress caused by reactive oxygen species, DNA damage caused by radiation-anticancer agents, and activation of oncogenes. Cellular senescence functions as a cancer suppression mechanism caused by the accumulation of DNA repair mechanisms, apoptosis, and gene mutations caused by DNA damage and mitochondrial disorders. However, it is known that senescent cells accumulated in the body induce chronic inflammation by highly expressing various inflammatory proteins and secreting SASP (Senescence-associated secretory phenotype) in surrounding tissues, which can cause various diseases and symptoms associated with aging, such as cancer. Therefore, controlling senescent cells or SASP in the body has the possibility of suppressing the onset of cancer or treating it.
[0003] The full picture of the mechanism of induction and control of cellular senescence is not yet clear, but senolytic drugs that selectively induce cell death in senescent cells and senomorphic drugs that inhibit SASP secreted by senescent cells are expected to have preventive and therapeutic effects on the onset of cancer associated with aging.
[0004] Therefore, senolytic drugs and senomorphic drugs are being studied as new cancer prevention drugs or therapeutic drugs. Patent document 1 discloses a complex for removing dysfunctional mitochondria and delivering a mitochondrial membrane potential reducer and a p53 inhibitor to target cells to inhibit cell senescence, and the mitochondrial membrane potential reducer is used to inhibit SASP. Patent document 2 discloses a cell senescence inhibitor that can inhibit cell senescence of stem cells.
[0005] However, the complex described in Patent Document 1 aims to remove dysfunctional mitochondria accompanying cell senescence, and therefore does not completely eliminate senescent cells. In addition, although the cell senescence inhibitor described in Patent Document 2 has confirmed an antioxidant effect, it is believed that it cannot eliminate cell senescence.
[0006] Prior art literature
[0007] Patent Literature
[0008] Patent Document 1: Japanese Patent Application Publication No. 2021-24852
[0009] Patent Document 2: Japanese Patent Application Publication No. 2018-52879
[0010] Non-patent literature
[0011] Non-patent literature 1: Casella G et al. Nucleic Acids Res 2019, Vol47(14), pp.7294-7305.
[0012] Non-patent document 2: Ting T et al, Science, 2011, Vol. 6017, pp. 593-596. doi: 10.1126 / science.1200801. Epub 2011 Jan 13.
[0013] Non-patent document 3: Kishikawa T et al, JCI Insight. 2016, Jun 2; 1(8): e86646. doi: 10.1172 / jci.insight.86646.
[0014] Non-patent document 4: Solovyov A Cell Rep, 2018, Vol. 23(2), pp. 512-521. doi: 10.1016 / j.celrep.2018.03.042.
[0015] Non-patent literature 5: Franses JW et al, Oncologist. 2018, Vol. 23(1): pp. 121-127, Published online 2017 Aug 31, doi: 10.1634 / theoncologist.2017-0234.
[0016] Non-patent literature 6: Billingsley KJ, Scientific Reports 2019, volume 9, Article number: 4369.
[0017] Non-patent literature 7: Oezguer E et al. Clin Chim Acta. 2021, Vol. 514, pp. 74-79. doi: 10.1016 / j.cca.2020.12.008. Epub 2020 Dec 31.
[0018] Non-patent literature 8: Cambier L et al, Scientific Reports, 2021, vol. 11, Article number: 94.
[0019] Non-patent literature 9: Nogalski, MT et al, Nature Communications. 2019, vol. 10, Article number: 90.
[0020] Non-patent literature 10: Bersani F et al, PNAS, 2015, 112(49), pp.11548-15153. https: / / doi.org / 10.1073 / pnas.1518008112.
[0021] Non-patent literature 11: Nogalski, MT et al, PNAS, 2020, Vol. 117(50), pp. 31891-31901, https: / / doi.org / 10.1073 / pnas.2017734117.
[0022] Non-patent literature 12: Kojima R et al., Nature Communications, 2018, vol. 9, Article number: 1305 (2018), DOI: 10.1038 / s41467-018-03733-8. Summary of the invention
[0023] Technical problem to be solved by the invention
[0024] As described in detail below, the inventors of the present invention have discovered that non-translated RNA that is not expressed in normal cells is highly expressed in senescent cells and cancer cells, and controls the expression of inflammatory gene groups. In addition, it was discovered that in senescent cells and cancer cells with high expression of non-translated RNA, cell death is induced by expression inhibition. Therefore, the technical problem is to provide a cancer treatment drug that targets the non-translated RNA and inhibits harmful SASP, thereby eliminating senescent cells in the cancer microenvironment. In addition, the technical problem is to provide an inspection method and inspection drug for diagnosing cancer by examining the non-translated RNA as a target or the molecule whose expression changes with it or the epigenome of the gene region. In addition, since a new target molecule for cancer treatment has been discovered, the technical problem is to provide a screening method for therapeutic drugs using the target molecule.
[0025] Technical solutions for solving technical problems
[0026] The present invention relates to the following therapeutic drugs, examination auxiliary methods and therapeutic drug screening methods.
[0027] (1) A pharmaceutical composition which is a therapeutic and / or preventive drug for cancer caused by senescent cells, wherein the pharmaceutical composition is characterized by suppressing the expression of hSATII RNA or inhibiting its activity and / or increasing the expression of CTCF.
[0028] It was found that the increase in hSATII RNA expression or the inhibition of its activity and the decrease in CTCF expression are closely related to the progression of cancer. Therefore, substances that can regulate them can treat cancers related to senescent cells.
[0029] (2) The pharmaceutical composition according to (1), characterized in that the pharmaceutical composition is a nucleic acid drug that inhibits the expression of hSATII RNA or inhibits its activity and / or increases the expression of CTCF.
[0030] In particular, as exemplified in the present specification, nucleic acids or compounds that regulate the expression or activity of hSATII RNA or CTCF are effective as pharmaceuticals.
[0031] (3) The pharmaceutical composition according to (1) or (2), wherein the pharmaceutical composition targets cancer cells and stromal cells.
[0032] The pharmaceutical composition targeting hSATII has an effect on both cancer cells and stromal cells that form the cancer microenvironment, and thus can be used for effective treatment.
[0033] (4) The pharmaceutical composition according to (3), characterized in that it is used in combination with a chemotherapeutic agent or radiotherapy.
[0034] If cellular senescence is induced by chemotherapy or radiotherapy, not only cancer cells but also stromal cells are induced to undergo cell death by the present pharmaceutical composition. Therefore, cell death can be induced in cancer cells that have not been induced to undergo cell death by existing chemotherapy or radiotherapy and stromal cells that form the cancer microenvironment. Therefore, the present pharmaceutical composition is not only effective in treating cancer, but also helps prevent recurrence.
[0035] (5) A method for assisting cancer detection, characterized in that the method comprises detecting hSATII RNA and / or CTCF expression in a sample.
[0036] Inflammatory gene groups such as SASP factors, which are induced to express along with cell senescence, can also be expressed due to inflammation that is independent of cell senescence. However, it is known that changes in the expression of hSATII RNA and CTCF are phenomena specific to cell senescence and are related to the onset of cancer. Therefore, by capturing changes in their expression, cancer caused by cell senescence can be detected.
[0037] (6) The examination supporting method according to (5), characterized in that when the expression of hSATII RNA increases and / or the expression of CTCF decreases, it is determined that the patient has cancer.
[0038] The pharmaceutical compositions described in (1) to (4) can be expected to exert high effects on cancers closely related to cell senescence. By examining whether cancer is caused by cell senescence, the most appropriate therapeutic drug can be provided.
[0039] (7) A method for assisting cancer detection, characterized in that the method comprises detecting epigenomic changes in the hSATII DNA region in a sample.
[0040] In the process of inducing a senescence-like phenotype in cancer cells, epigenomic changes such as relaxation (swelling) and increased accessibility of the hSATII region of genomic DNA occur before the increase in hSATII RNA expression and / or the decrease in CTCF expression. Therefore, methods for detecting these changes can be effective testing methods for detecting cancer.
[0041] (8) The inspection assisting method according to (7), characterized in that it assists the inspection of cancer caused by cell senescence.
[0042] Epigenomic changes such as relaxation and increased accessibility of the hSATII region of genomic DNA are believed to occur at the very early stage of cancer development, and thus, by detecting these changes, there is the possibility that cancer can be detected at an early stage.
[0043] (9) A method for screening therapeutic and / or preventive drugs for cancer, which is a method for screening therapeutic and / or preventive drugs for cancer caused by cellular senescence, the method being characterized in that a candidate compound is added to the culture medium of senescent cells, and the candidate compound is selected based on at least any one of the following as an indicator: reduction in hSATII RNA expression, inhibition of hSATII RNA activity, increase in CTCF expression, reduction in SASP factor expression, shrinkage of hSATII DNA region, and reduction in chromatin accessibility.
[0044] By using changes specific to cell senescence as indicators, it is possible to screen for new cancer therapeutic drugs. In particular, epigenomic changes such as increased and activated hSATII RNA expression, decreased CTCF expression, and loosening and increased accessibility of the hSATII region of genomic DNA are phenomena specific to senescent cells, so by detecting these changes, it is possible to screen for senolytic drugs and senomorphic drugs related to cancer therapeutic drugs.
[0045] (10) A method for treating cancer associated with cellular senescence, comprising detecting whether the onset or progression of cancer is associated with senescent cells, or detecting cancer or stromal cells by the auxiliary examination method described in any one of (5) to (8), and administering the therapeutic drug described in (1) to (4) to treat the disease.
[0046] (11) A method for treating cancer, which is a method for treating cancer associated with cellular senescence, wherein the method comprises administering a compound that suppresses the expression of hSATII RNA or inhibits its activity and / or increases the expression of CTCF. BRIEF DESCRIPTION OF THE DRAWINGS
[0047] Figure 1A Screening scheme for transcripts associated with increased chromatin accessibility (a); volcano plot showing changes in ATAC-seq peaks in IMR-90 cells during proliferation and after senescence induced by X-rays (b); 652 transcripts with changes in chromatin accessibility shown in the volcano plot of RNA-seq data (GSE130727) (c). In (b) and (c), the horizontal axis FC represents fold change, and the vertical axis represents FDR.
[0048] Figure 1B Peaks of ATAC-seq and RNA-seq (GSE130727) data at the hSATII locus in IMR-90 cells during proliferation and after cell senescence was induced by X-rays. Results from two biological replicates are shown. In ATAC-Seq and RNA-Seq, the top two columns show the results obtained in IMR-90 cells during proliferation, and the bottom two columns show the results in IMR-90 cells after cell senescence was induced.
[0049] Figure 2 The graph shows the results of analyzing the expression of hSATII RNA in various cancer cells.
[0050] Figure 3A It is a heat map of the expression of SASP-related genes in SVts8 cells overexpressing non-translated RNA from centromere (hSATα) or non-translated RNA from paracentromere region (hSATII) and X-ray-induced senescent SVts8 cells.
[0051] Figure 3B It is a scatter plot showing the changes in chromatin accessibility in hSATα (x-axis) or hSATII (y-axis) RNA-overexpressing SVts8 cells compared with vector-expressing cells.
[0052] Figure 3CEnrichment analysis of gene sets associated with cell senescence (upper) and inflammatory response (lower) in SVts8 cells overexpressing hSATα or hSATII RNA.
[0053] Figure 3D The graph shows the results of RT-qPCR analysis of the effect of hSATII RNA knockdown on SASP gene expression in proliferating SVts8 cells or cells induced to senescence by X-rays. ***P<0.001.
[0054] Figure 4A The results of Gene Ontology analysis of 280 hSATII RNA binding proteins identified by mass spectrometry (left). Among them, 26 proteins were classified as chromatin binding (GO: 0003682). The top 10 genes and the number of unique peptides are summarized on the right.
[0055] Figure 4B The graph shows the results of a pull-down assay of hSATα or hSATII RNA using SVts8 cell lysate and Western blotting analysis of the binding to CTCF.
[0056] Figure 4C The graph shows the results of Western blotting analysis of the expression of each molecule after expressing FLAG-tagged CTCF (wild type), CTCFΔZF1-11 (mutant), and CTCFΔZF3-6 (mutant) in HEK-293T cells.
[0057] Figure 4D The graph shows the results of RIP-qPCR analysis of the binding of FLAG-tagged CTCFWT, CTCFΔZF1-11, or ΔZF3-6 expressed in HEK-293T cells to hSATII RNA. NS: Not significant, ***P<0.001.
[0058] Figure 5A This is a graph showing the results of RT-qPCR analysis of the effect of hSATII RNA expression on the expression of SASP-like inflammation-related genes in CTCF-forced SVts8 cells. The relative expression level is the value normalized by the value of vector-expressing cells. *P<0.05, **P<0.01, ***P<0.001.
[0059] Figure 5BThis is a graph showing the results of RT-qPCR analysis of the expression of SASP-like inflammation-related genes in SVts8 cells in which CTCF expression was suppressed by siRNA. The relative expression levels were normalized from the values of cells treated with control siRNA. *P<0.05, **P<0.01, ***P<0.001.
[0060] Figure 5C This is a graph showing the results of RT-qPCR analysis of hSATII RNA, CTCF, and the expression of genes related to cell senescence and inflammation in TIG-3 cells induced by subculture. The expression level of each gene is a value normalized to the expression level at the beginning of subculture. ***P<0.001.
[0061] Figure 5D The graph shows the results of Western blotting analysis of the decrease in CTCF protein and the expression of cellular senescence marker proteins in TIG-3 cells induced to senescence by subculture.
[0062] Fig. 6A It is a Venn diagram showing the changes in CTCF binding peaks obtained by ChIP-seq analysis.
[0063] Figure 6B The following are the profiles of the signals in the central ±2 kb region of the peak obtained by ChIP-seq analysis (left) and the heat map of the two clusters divided by the k-means algorithm (right). The P value of the Wilcoxon rank sum test is shown.
[0064] Figure 6C The graph shows the results of ChIP-qPCR analysis of the effect of hSATII RNA on CTCF binding to the ICR located between IGF2 and H19.
[0065] Fig.6D The graph shows the results of EMSA analysis of the effect of hSATα or hSATII RNA on the binding of CTCF to genomic DNA.
[0066] Fig. 6E The diagram shows RNA-seq, CTCF ChIP-seq, and ATAC-seq profiles of the gene loci of CXCL10 and CXCL11, which are representative SASP factors.
[0067] Fig. 6FThis is a graph showing that hSATII RNA weakens chromatin interactions in 3C-qPCR assays. It shows the relative interactions between the constant region (C) and each target region (T). NS: Not significant, *P<0.05.
[0068] Fig. 7A The figure shows the results of confirming the expression of hSATII RNA introduced by retrovirus in SVts8 cells by RT-PCR.
[0069] Figure 7B The left side of the figure shows that the expression of hSATII RNA increases the number of multipolar cells. The figure shows the microscopic image and the ratio of multipolar cells. **P<0.01. The right side of the figure shows that the expression of hSATII RNA increases the number of cells with chromosome bridges. The figure shows the microscopic image and the ratio of multipolar cells. **P<0.001.
[0070] Figure 7C The graph shows the results of karyotype analysis (n=20) of SVts8 cells overexpressing hSATII RNA. ***P<0.001.
[0071] Fig.7D This is a graph showing the scaffold-independent proliferation ability of SVts8 cells overexpressing hSATII RNA. *P<0.05.
[0072] Fig. 7E The left side is an immunostaining image showing the effect of hSATII RNA expression on multipolarization in SVts8 cells overexpressing CTCF. The right side is a graph showing the proportion of multipolar cells generated by hSATII RNA expression in SVts8 cells overexpressing CTCF. *P<0.05, **P<0.01.
[0073] Fig. 8A The figure shows the results of RT-PCR verification of the expression of MajSAT RNA introduced by retrovirus in mouse embryonic fibroblasts MEFs.
[0074] Figure 8B The left side is a graph showing that the expression of MajSAT RNA increased the number of multipolar cells. The right side shows the microscopic images and the ratio of multipolar cells. *P<0.05.
[0075] The right side is a graph showing that the number of cells with chromosome bridges increased due to the expression of MajSAT RNA. Microscope images and the ratio of cells with chromosome cross-links are shown. *P<0.05.
[0076] Figure 8C This is a graph showing the scaffold-independent proliferation ability of MEFs overexpressing MajSAT RNA. ***P<0.001.
[0077] Fig.8D The graph shows the results of karyotype analysis (n=20) of MEFs overexpressing MajSAT RNA. ***P<0.001.
[0078] Fig. 8E The figures show the weights of tumors (left) and photographs (right) on day 20 (MEF / MajSAT RNA#2) or day 30 (MEF / Vector, MEF / MajSAT RNA#1, MEF / MajSAT RNA#3) after MEFs overexpressing MajSAT RNA were transplanted subcutaneously into nude mice. **P<0.01.
[0079] Fig. 9A These are the results of RT-qPCR analysis of hSATII and hSATα RNA contained in extracellular vesicles from RPE-1 / hTERT cells. *P<0.05, ***P<0.001.
[0080] Fig. 9B Expression of SASP-like inflammation-related genes in designer exosomes produced by the EXOtic device was evaluated by RT-qPCR. Values were normalized by cells treated with EXOtic-Nluc.
[0081] Fig. 9C This is a box plot obtained by quantifying the results of RNA-ISH using hSATII RNA probe in colorectal cancer specimens. It shows the hSATII RNA-positive cell rate in normal epithelial cells and tumor cells (left), and normal fibroblasts and cancer-associated fibroblasts (right). The upper and lower vertical lines represent the third or first quartile, respectively, and the upper and lower whiskers represent the highest and lowest values within 1.5 times the interquartile range. The horizontal line in the box represents the median. The horizontal line in the box represents the median. **P<0.01, ***P<0.001.
[0082] Fig.9D This is a diagram schematically showing the mechanism by which the increased expression of hSATII RNA from the pericentromeric region accompanying cell senescence induces the expression of SASP-related inflammatory genes.
[0083] Fig. 10A The graph shows the results of analyzing the effects of inhibiting hSATII expression by siRNA in pancreatic cancer cells and pancreatic stromal cells in which cell senescence was induced.
[0084] Fig. 10BThis is a diagram showing the results of RNA-ISH analysis of hSATII expression in breast cancer patient specimens. It was confirmed that hSATII RNA is expressed not only in cancer cells but also in stromal cells.
[0085] Fig.11A The graph shows the results of analyzing the anti-tumor effect of suppressing hSATII RNA expression using siRNA after pancreatic cancer cells were transplanted into immunodeficient mice.
[0086] Fig. 11B The figure shows the results of analyzing the anti-tumor effect of suppressing the expression of hSATII RNA in the stromal cells by siRNA in a system in which pancreatic cancer cells and stromal cells induced to cell senescence were co-transplanted into immunodeficient mice.
[0087] Fig. 12A The results of DNA-FISH analysis of the opening of the hSATII DNA region and gene expression at each passage number when TIG-3 cells were induced to undergo cell senescence by subculture, and RT-qPCR analysis of the expression changes of gene groups associated with cell senescence. NS: Not significant, ***P<0.001.
[0088] Fig. 12B The chromatin accessibility scatter plot of the hSATIIDNA region was drawn based on DNaseI sequencing data of various cancer cell lines.
[0089] Fig. 12C The results of scATAC-seq analysis of the open state of the hSATII DNA region in breast cancer patient specimens are shown.
[0090] Fig.12D The results of the analysis of the opening of the hSATII DNA region in breast cancer patient specimens by DNA-FISH analysis are shown.
[0091] Fig.12E The results of the analysis of the opening of the hSAT DNA region in breast cancer patient specimens are shown.
[0092] Fig.13 This is a diagram schematically showing one method of screening.
[0093] Fig.14 This is a diagram schematically showing the function of hSATII RNA and the concept of seno-cancer therapy targeting hSATII RNA. DETAILED DESCRIPTION
[0094] Although the following specifically describes the data, the present invention is not limited to these.
[0095] The therapeutic drugs shown below are effective as therapeutic drugs for cancers that develop due to aging. In particular, cancers that are closely related to inflammation and onset, such as breast cancer, colorectal cancer, and pancreatic cancer, whose number of patients increases due to aging, can be cited.
[0096] The therapeutic drugs shown below target non-translated RNA expressed in senescent cells, so they can not only inhibit diseases that have already occurred, but also inhibit the onset of cancer caused by cell senescence. Therefore, they can also achieve effects on the prevention of cancer onset and recurrence. Regarding the method of administration, it can be administered according to the commonly used administration method.
[0097] In this specification, "cellular senescence (or simply senescence)" refers to a state in which normal cells irreversibly stop proliferating due to a continuous DNA damage response. Cells that have undergone cellular senescence are called senescent cells, which secrete SASP factors such as inflammatory proteins and extracellular vesicles. In addition, "cellular senescence-like" refers to a state in which the expression of inflammatory gene groups increases in normal cells or cancer cells, and inflammatory protein groups, extracellular vesicles, etc. are secreted. Cellular senescence is a different concept from the aging of individuals in humans and animals. Individual aging is physical age, but cellular senescence is biological aging, and the increase of senescent cells depends on how much stress the cells are subjected to. In addition, "cancer" is a broad definition of the state of all neoplasms, regardless of malignancy or benignity. It includes both solid cancer and non-solid cancer (hematological cancer). "Cancer cells" and "tumor cells" are synonymous. In addition, "stromal cells" refers to the general term for cells that constitute the supporting tissue of epithelial cells, including immune cells such as fibroblasts, lymphocytes or macrophages, vascular endothelial cells, smooth muscle cells, etc. Cancer-associated fibroblasts (CAFs) are stromal cells that constitute the cancer stroma and are known to produce various growth factors that promote the proliferation of cancer cells.
[0098] Substances secreted as SASP factors include inflammatory proteins such as inflammatory cytokines, chemokines, matrix degrading enzymes, and growth factors, and extracellular vesicles such as exosomes. As inflammatory proteins, they specifically include: inflammatory cytokines such as TNF-α, IL-1, and IL-6, CC chemokines identified as CCL1 to CCL28, CXC chemokines identified as CXCL1 to CXCL17, C chemokines of XCL1 and XCL2, CX3C chemokines of CX3CL1, matrix degrading enzymes identified as MMP1 to MMP28, and growth factors such as TGF-β, BMP, FGF, PDGF, and HGF. In addition, various substances secreted in association with inflammation may also be included.
[0099] In addition, whether the disease or condition is effective for the therapeutic agent of the present invention can be determined by the following detailed tests. Performing a test in advance to determine whether the therapeutic agent is effective is not only important for selecting an appropriate treatment method for the patient, but also important from a medical economic perspective.
[0100] [Analysis of transcripts with altered expression in senescent cells]
[0101] The following describes the therapeutic targets for cancers caused by cellular senescence while presenting data. In addition, the experimental methods such as test methods used below are based on methods commonly performed in the field unless otherwise specified.
[0102] It has been reported that cells undergoing cellular senescence show abnormal nuclear morphology, and that the expression of inflammatory genes is induced by the activation of the cytoplasmic nucleic acid recognition mechanism. Furthermore, it is known that cell senescence induces a major change in chromatin structure and changes in gene expression. Therefore, in order to clarify the mechanism of changes in chromatin structure and gene expression during cell senescence, the accessibility of chromatin and changes in RNA expression in senescent cells and normal cells were compared.
[0103] ATAC-seq (assay for transposase-accessible chromatin sequencing) was performed using normal human diploid fibroblasts IMR-90 (obtained from ATCC) in the proliferation phase and cells induced to cell senescence by X-rays. It was found that during the process of cell senescence, 16,325 regions (false discovery rate < 0.05) changed ( Figure 1A , (a)).
[0104] According to the results of ATAC-seq, in IMR-90 cells induced by X-ray senescence, there were 14,356 peaks with increased chromatin accessibility and 1,969 peaks with decreased chromatin accessibility ( Figure 1A , (b)). 16,325 regions with changes in chromatin accessibility were annotated for 652 transcripts using databases including GRCh37 / hg19 and RepeatMasker.
[0105] The 652 transcripts were reanalyzed using data on their expression levels (GSE130727, Non-Patent Document 1). Figure 1A (c)). The expression levels were analyzed using RNA-seq data of IMR-90 cells in the proliferation phase and after cell senescence was induced by X-rays (GSE130727). The results showed that the hSATII (human satellite II) locus, a repetitive sequence present in the pericentromere region, was highly accessible in IMR-90 cells after cell senescence was induced by X-rays ( Figure 1A , (b)), and its expression was significantly increased compared with that of cells in the proliferation phase (log 10 fold change(log 10 Fold change) = 2.8, Figure 1A , (c)).
[0106] When ATAC-seq data and RNA-seq data (GSE130727) of proliferating and X-ray-induced senescence IMR-90 cells were combined, chromatin accessibility and transcription of the hSATII locus were increased in senescent cells compared with proliferating cells ( Figure 1B ). The data are not presented here, but induction of cell senescence through subculture and expression of the oncogene H-Ras V12 hSATII RNA expression was also detected in IMR-90 cells and normal diploid fibroblasts TIG-3 cells that were cultured for a long time, accompanying cell senescence.
[0107] Regarding hSATII RNA, the enhancement of RNA transcription was first confirmed in pancreatic cancer cells (Non-Patent Document 2), and high expression was also reported in colorectal cancer, Parkinson's disease, and viral infections, and candidates for diagnostic markers for cancer were disclosed (Non-Patent Documents 3 to 9). In addition, the use of LNA targeting hSATII RNA to inhibit the proliferation of cancer cells or tumors was also disclosed (Non-Patent Documents 10 to 11).
[0108] Therefore, the expression level of hSATII RNA in cell lines from lung cancer, colorectal cancer, gastric cancer, breast cancer, pancreatic cancer, and two normal cell lines (RPE-1 and TIG-3) was analyzed by RT-qPCR ( Figure 2 ). In addition, cells were obtained as follows. A549, BSY1, HBC4, HCC2998, HCT15, HCT116, MKN1, MKN74, NCI-H460, ST4, DMS273, HT29, NCI-H226, NCI-H23 (Human Cancer Cell Line Panel JFCR39), MDA-MB-468, SW620, MDA-MB-231 (ECACC), RPE-1, MCF7 (JCRB Cell Bank) RPE-1, T47D (ATCC), MiaPaCa (Riken Cell Bank). In addition, for normal cells, the expression level of hSATII RNA was analyzed using cells induced to cell senescence by the anticancer agent doxorubicin and cells cultured normally. Although there were differences in expression levels in cancer cells, high expression of hSATII RNA was confirmed in any of the cells compared with normal cells cultured normally. In addition, it was found that when cell senescence was induced in normal cells, the expression increased significantly.
[0109] [Changes caused by hSATII RNA expression]
[0110] An analysis was conducted to determine the biological effects of hSATII RNA expression. Using SVts8 cells (a cell line in which the temperature-sensitive SV40-Large T antigen gene was introduced into TIG-3 cells), an immortalized human fibroblast cell line, hSATII RNA was overexpressed. According to the results of RNA-Seq, overexpression of hSATII RNA induced the expression of SASP-like inflammatory gene groups. On the other hand, no expression of inflammatory gene groups was found in the overexpression of human satellite α RNA (hSATα) located in the centromere region ( Figure 3A ). In addition, it was shown that the region of the inflammatory gene group became open due to the overexpression of hSATII RNA, but it did not appear in hSATα RNA ( Figure 3B ). In the expression analysis of gene groups related to inflammatory response and SASP, it was also suggested that overexpression of hSATII RNA increased the expression of SASP-like inflammatory genes ( Figure 3C The inventors of the present invention first discovered that hSATII RNA is expressed in senescent cells and controls the expression of inflammatory gene groups.
[0111] In addition, hSATII RNA was knocked down using siRNA in SVts8 cells in the proliferation phase and in which cell senescence was induced by X-rays, and the expression of CXCL10, IL1A, and IFNB1, which are SASP-related genes, was analyzed. hSATII RNA was knocked down by introducing siRNA into SVts8 cells using Lipofectamine RNAiMAX transfection reagent (Thermo Fisher Scientific). The following siRNA sequences were used for transfection at a concentration of 20 nM, and the expression of each gene was analyzed by RT-qPCR 2 days later.
[0112] hSATII siRNA
[0113] #1: 5′-UUUCCAUUCC AUUCCAUUC-3′(sequence number 1)
[0114] #2: 5′-AAUCAUCGAA UGGUCUCGA-3′ (sequence number 2)
[0115] Comparison
[0116] 5′-AUGAACGUGA AUUGCUCAA-3′(SEQ ID NO. 3)
[0117] In addition, the expression levels of hSATII, CXCL10, IL1A, and IFNB1 were analyzed by RT-qPCR. Total RNA was extracted with TRIzol reagent (Thermo Fisher Scientific), and after removing the implicated DNA with TURBO DNA-free kit (Applied Biosystems), reverse transcription was performed with PrimeScript RT Master Mix (TaKaRa). RT-qPCR was performed with SYBR Premix Ex TaqII (TaKaRa) and StepOne Plus PCR system (ThermoFisher Scientific). The following primers were used.
[0118] hSATII
[0119] Forward primer: 5′-AATCATCGAA TGGTCTCGAT-3′ (SEQ ID NO: 4)
[0120] Reverse primer: 5′-ATAATTCCAT TCGATTCCAC-3′ (SEQ ID NO: 5)
[0121] CXCL10
[0122] Forward primer: 5′-CCAGAATCGAAGGCCATCAA-3′ (SEQ ID NO: 6)
[0123] Reverse primer: 5′-CATTTCCTTGCTAACTGCTTTCAG-3′ (SEQ ID NO: 7)
[0124] IL1A
[0125] Forward primer: 5′-AACCAGTGCTGCTGAAGGA-3′ (SEQ ID NO: 8)
[0126] Reverse primer: 5′-TTCTTAGTGCCGTGAGTTTCC-3′ (SEQ ID NO: 9)
[0127] IFNB1
[0128] Forward primer: 5′-AAACTCATGAGCAGTCTGCA-3′ (SEQ ID NO: 10)
[0129] Reverse primer: 5′-AGGAGATCTTCAGTTTCGGAGG-3′ (SEQ ID NO: 11)
[0130] If hSATII RNA is knocked out, the expression of CXCL10, IL1A, and INFB1 in senescent cells is reduced. Figure 3D In the figure, the expression of proliferating cells treated with control siRNA was set as 1, and the relative expression level was expressed as fold change (FC). In addition, although not shown here, the same results were also shown in senescent cells formed by subculture of IMR-90 cells. These data suggest that hSATII RNA changes chromatin accessibility with cell senescence, thereby controlling the expression of SASP-like inflammation-related genes.
[0131] [Control mechanism of inflammation-related genes via hSATII RNA]
[0132] In order to analyze the mechanism of promoting the expression of SASP-like inflammation-related genes caused by hSATII RNA, we attempted to identify hSATII RNA binding proteins. Although there are reports on the correlation between hSATα RNA located in the centromere region and specific proteins, there are no reports on hSATII RNA located in the paracentromere region. Therefore, RNA pull-down and mass spectrometry analysis were performed to identify 280 hSATII RNA binding proteins.
[0133] From these proteins, 26 chromatin-binding proteins (GO: 0003682) were identified by gene ontology analysis. Considering the intensity scores obtained by mass spectrometry analysis and the large number of reports that it helps maintain the three-dimensional structure of chromatin, we decided to focus on CTCF ( Figure 4A ). The binding of hSATII RNA to CTCF was confirmed by RNA pull-down assay. After RNA pull-down assay, SVts8 cell lysate was analyzed by Western blotting. It was confirmed that hSATII RNA bound to CTCF, but hSATα RNA did not bind to CTCF ( Figure 4B ).
[0134] It is known that the binding of CTCF to genomic DNA is important for maintaining the proper three-dimensional structure of the genome. Since CTCF is also an RNA-binding protein, RNA immunoprecipitation (RIP) was performed. Wild-type CTCF (WT) and CTCF ZF (Zinc Finger)-deficient mutants ΔZF1-11 and ΔZF3-6 were expressed in HEK293T cells. Figure 4C hSATIIRNA was found to bind to wild-type CTCF, but not to the CTCF variants ΔZF1-11 and ΔZF3-6 ( Figure 4D ). There are 11 ZF domains in CTCF, and it is believed that the binding of ZF1 or ZF10 to RNA is important for the formation of chromatin loops to control gene expression. However, although the data are not shown here, it is known that hSATII RNA does not bind to either ZF1 or ZF10. The ZF3-ZF6-deficient variant of CTCF (CTCFΔZF3-6), which is known as a DNA binding domain, cannot bind to hSATII RNA, so it is known that ZF3-ZF6 is important in binding to hSATII RNA.
[0135] In SVts8 cells in which CTCF was forced to be expressed and hSATII RNA was overexpressed, the expression of inflammation-related gene groups was analyzed by RT-qPCR ( Figure 5A ). In the case of overexpression of CTCF, even if hSATII RNA was expressed, its effect was lost, and no enhancement of the expression of inflammation-related genes was found. In addition, in proliferating cells, CTCF was knocked out using CTCF siRNA (Thermo Fisher Scientific, #HSS116455, #HSS116456, Negative Control (Duplex High GC Duplex) siRNA, #46-2000), and the expression of inflammation-related gene groups was analyzed ( Figure 5B). If CTCF is knocked out, the expression of inflammation-related genes is enhanced. Unexpectedly, it was found that the expression of hSATII RNA also increased by knocking out CTCF. Based on these results, it is suggested that the expression of the inflammation-related gene group induced by hSATII RNA is likely to depend on the functional inhibition of CTCF, and CTCF controls the expression of hSATII RNA during cell aging. Therefore, in TIG-3 cells induced to age by subculture, the expression level of CTCF was analyzed by RT-qPCR and Western blotting ( Figure 5C , D). As the subculture progresses, the expression level of CTCF decreases ( Figure 5C , D), the expression of hSATII RNA and inflammation-related genes increased ( Figure 5C ). Therefore, it is suggested that CTCF controls the expression of hSATII RNA during cell senescence.
[0136] In addition, although the data are not shown here, the expression of major satellite (MajSAT) RNA located in the paracentromere region of mice was analyzed in the same way as human hSATII RNA. It was found that when cell senescence was induced by causing DNA damage in mouse embryonic fibroblasts (MEF) using doxorubicin, the expression of SASP-related inflammatory gene groups and MajSAT RNA increased. In other words, it was shown that in the case of mice, the induction of MajSAT RNA was negatively correlated with the expression of CTCF. In addition, CTCF does not bind to Minor Satellite (MinSAT) RNA present in the centromere of mice, but binds to MajSAT RNA present in the paracentromere region, increasing the expression of SASP-related inflammatory gene groups. Based on these findings, it is shown that CTCF is important for controlling the expression of satellite RNA and SASP-related inflammatory gene groups in the paracentromere region during cell senescence.
[0137] [Mechanism of action of hSATII RNA]
[0138] The ZF3-ZF6 DNA binding domain of CTCF is associated with binding to hSATII RNA. Therefore, we hypothesized that direct binding of hSATII RNA to the ZF domain of CTCF might change the DNA binding ability, and conducted the following study. hSATII RNA was expressed and ChIP-Seq was performed ( Fig. 6A, B). As expected, the binding peak of CTCF was changed by overexpression of hSATII RNA. Therefore, the binding ability of CTCF to the ICR (imprinting control region) between IGF2 and H19, the representative binding site of CTCF, was analyzed by ChIP-qPCR and EMSA (Electrophoretic Mobility Shift Assay). Figure 6C , D) It was confirmed that the DNA binding ability of CTCF was reduced by hSATII RNA expression, and it was found that hSATII inhibited its binding in an RNA concentration-dependent manner.
[0139] hSATII RNA changes the interaction with chromatin through the binding of CTCF to DNA. Therefore, it is suggested that it is important for maintaining the proper three-dimensional structure of the genome. For this reason, hSATII RNA was expressed, and a chromosome conformation capture (3C) experiment was performed near the CXCL10 / CXCL11 locus, which is a SASP gene. The results showed that the interaction between the T2 and T22 regions was significantly weakened by overexpression of hSATII RNA. In addition, ATAC-seq analysis confirmed that the chromatin accessibility within the locus increased and the expression of the SASP-related inflammatory gene group increased. In addition, the same phenomenon was also confirmed in senescent cells induced by X-rays ( Fig. 6E , F). These results suggest that the increased expression of hSATII RNA in senescent cells causes conformational changes in chromatin structure in the SASP locus. So far, the molecular mechanism of the correlation between CTCF control and SASP gene expression in cell senescence has not been elucidated, but it is known that satellite RNA in the pericentromeric region affects chromatin interaction by inhibiting the function of CTCF, causing changes in the expression of SASP-related inflammation-related genes.
[0140] [Effect of hSATII RNA on tumors]
[0141] It has been reported that satellite RNA from humans or mice induces chromosomal instability and has the potential to cause tumor formation. Therefore, SVts8 cells were forced to express SATII RNA ( Fig. 7A ), and immunostaining was used to analyze multipolarization and chromosome bridge formation, typical features of chromosome instability ( Figure 7B). Microtubules were stained with anti-α-tubulin antibody (Sigma-Aldrich), centrosomes were stained with pericentriolar protein (Abcam), and DNA was stained with DAPI (Thermo Fisher Scientific). The proportion of multipolar cells increased significantly in cells in which hSATII RNA was forced to be expressed ( Figure 7B Left). In addition, the number of cells that developed chromosome bridges also increased significantly in cells in which hSATII RNA was forcibly expressed ( Figure 7B right).
[0142] In addition, cells forced to express hSATII RNA showed phenotypes such as abnormal chromosome number and scaffold-independent proliferation, which are seen in tumor cells. Karyotype analysis revealed that cells showing abnormal chromosome number increased significantly in cells forced to express hSATII RNA ( Figure 7C In addition, a soft agar colony formation assay was performed to analyze whether scaffold-independent proliferation was produced by hSATII RNA expression. The results showed that scaffold-independent proliferation of colonies increased significantly by hSATII RNA expression ( Fig.7D ).
[0143] Next, we investigated whether simultaneous overexpression of hSATII RNA and CTCF would affect chromosomal instability induced by hSATII RNA. Figure 7B The ratio of multipolar cells was also analyzed. The results showed that if CTCF was expressed, the chromosomal instability induced by hSATII RNA disappeared ( Fig. 7E ). This suggests that CTCF is associated with chromosomal instability induced by hSATII RNA and is a risk factor for tumorigenesis.
[0144] Figure 8 shows the results of ectopic expression of MajSAT RNA using mouse embryonic fibroblasts (MEFs). As in Figure 7, MEFs were forced to express MajSAT RNA ( Fig. 8A ), and observed multipolarization and chromosome bridge formation by microscopy ( Figure 8B By forcing the expression of MajSAT RNA, both multipolarization and chromosome bridge formation were significantly increased. In addition, scaffold-independent proliferation ( Figure 8C )、karyotype( Fig.8D ) were also analyzed, and the results showed that the number of transformed cells and chromosome abnormalities that proliferated independently of the scaffold increased significantly through MajSAT RNA expression. In addition, these cells were transplanted subcutaneously into nude mice and the results showed tumor formation ability ( Fig. 8E ). Therefore, it was concluded that the satellite RNA in the pericentromeric region has the potential to promote carcinogenesis.
[0145] Next, we analyzed the function of hSATII RNA in the tumor microenvironment. It was found that extracellular vesicles secreted from cancer cells and senescent stromal cells are involved in the occurrence and progression of tumors in the cancer microenvironment. RPE-1 / hTERT cells (obtained from ATCC) were induced to senescence by doxorubicin (DXR) or 40-gray X-ray irradiation (XRA). RT-qPCR was performed on the extracellular vesicles recovered from these cells, and the results showed that the amount of hSATII RNA in the extracellular vesicles from senescent cells was significantly higher than that in the extracellular vesicles from proliferating cells. However, no increase in the amount of hSATα RNA was confirmed ( Fig. 9A ).
[0146] It has been reported that hSATII RNA was detected in extracellular vesicles (exosomes) secreted from multiple human colorectal cancer cell lines based on the analysis of RNA-seq data. It can be inferred that hSATII RNA from senescent mesenchymal cells is transferred to surrounding cells via extracellular vesicles and functions as a SASP-like inflammatory factor. Although no data are shown here, the inventors of the present invention have confirmed that extracellular vesicles from senescent cells induce scaffold-independent proliferation and chromosomal instability of normal cells. Therefore, in order to evaluate the involvement of hSATII RNA contained in extracellular vesicles, a synthetic biology method using the EXOtic device (EXOsomal transfer into cells) (non-patent document 12) was used to construct designer exosomes containing hSATII RNA. The produced designed exosomes were taken into SVts8 cells, and the expression of inflammation-related genes was analyzed by RT-qPCR. It was confirmed that the expression of SASP-like inflammation-related genes was promoted by the designed exosomes containing hSATII RNA ( Fig. 9B ). That is, it was found that the designed exosomes produced had the same tumorigenic activity as extracellular vesicles from senescent cells. Therefore, it was shown that hSATII RNA contained in exosomes secreted from senescent cells promoted SASP-like inflammation-related gene expression and chromosomal instability in stromal cells in the tumor microenvironment.
[0147] Using surgical resection specimens from patients with primary colorectal cancer, the expression of hSATII RNA in the tumor microenvironment was analyzed by RNA in situ hybridization (RNA-ISH). The results showed that colorectal cancer cells expressing hSATII RNA had significantly more ( Fig. 9CLeft). In addition, the proportion of hSATII RNA-positive cells in cancer-associated fibroblasts was significantly higher than that in fibroblasts of normal stromal tissues ( Fig. 9C Right). Therefore, it is suggested that senescent stromal cells expressing hSATII RNA promote tumor formation in the tumor microenvironment through the secretion of extracellular vesicles containing SASP-like inflammatory factors and hSATII RNA ( Fig.9D ).
[0148] As described above, it is believed that senescent stromal cells expressing hSATII RNA form a cancer microenvironment and promote tumor formation. Therefore, we analyzed whether inhibiting the expression of hSATII RNA affects the proliferation inhibition of cancer cells and stromal cells. hSATII siRNA was introduced into pancreatic cancer cells PANC-1 and normal pancreatic stromal cells hPSC (obtained from ScienCell), and the expression was analyzed by RT-qPCR ( Fig. 10A If gemcitabine is added to the culture medium to induce cell senescence, the expression of hSATII RNA increases in all cells. At the same time, the cell survival test CellTiter-Glo (Promega) was performed. In pancreatic cancer cells, when the expression of hSATII RNA was inhibited by siRNA, it was confirmed that the cell survival rate was significantly reduced ( Fig. 10A On the other hand, in normal pancreatic stromal cells, even if hSATII RNA expression was suppressed by siRNA, cell death was not induced, but in the case of cell senescence induced by gemcitabine, cell death was induced in pancreatic stromal cells ( Fig. 10A The results mean that when anticancer drugs are administered to induce cell senescence in stromal cells and inhibit the expression of hSATII RNA, cell death can be induced not only in cancer cells but also in stromal cells that form the cancer microenvironment. Therefore, more effective cancer treatment can be performed by inhibiting hSATII RNA.
[0149] Since pancreatic cancer cells are used here, gemcitabine, which is commonly used in the treatment of pancreatic cancer, is used, but cell senescence can be induced with any anticancer agent. In addition, cell senescence can be induced not only by anticancer agents, but also by radiation exposure. This shows that in the treatment of cancer, when anticancer agents are used or radiotherapy is performed, a higher effect can be obtained by combining a treatment that reduces the expression of hSATII RNA. In addition, it is believed that by the treatment of anticancer agents, etc., the remaining cancer cells or interstitial cells undergo cell senescence through treatment, so these cells can also be killed by simultaneously administering a pharmaceutical composition that reduces the expression of hSATII RNA. Therefore, when selecting an anticancer agent according to the type of cancer or performing radiotherapy, the recurrence of cancer can be suppressed by combining the treatment of an expression inhibitor of hSATII RNA.
[0150] The expression of hSATII RNA was analyzed using samples from breast cancer patients. The results of RNA-ISH showed that hSATII RNA was expressed not only in cancer cells but also in CAFs in the stroma ( Fig. 10B ). Therefore, it is believed that the pharmaceutical composition that inhibits the expression of hSATII RNA can become a therapeutic drug that targets not only cancer cells but also stromal cells that form the cancer microenvironment.
[0151] We analyzed whether inhibition of hSATII RNA expression could have a therapeutic effect on cancer. After pancreatic cancer cells PANC-1 were transplanted into immunodeficient mice, hSATII siRNA was introduced and the size of the tumor was measured ( Fig.11A ). As a result, when hSATII expression was suppressed by siRNA in pancreatic cancer, cancer cell proliferation was significantly suppressed compared with the case of administration of control siRNA. That is, it was shown that the pharmaceutical composition that suppresses the expression of hSATII RNA suppresses the growth of cancer.
[0152] Next, the effect of hSATII RNA expression inhibition in the co-transplantation system of cancer cells and stromal cells was analyzed. Normal pancreatic stromal cells hPSC were induced to cell senescence by X-ray irradiation (Day 0). Then, siRNA targeting hSATII or control siRNA was transfected (Day 10, Day 12), pancreatic cancer cells MIAPaCa2 and hPSC were mixed at a ratio of 1:2 and transplanted into mice, and the size of the tumor was measured once a week (refer to Fig. 11B , upper paragraph). On Day 48 after transplantation, it was confirmed that both the tumor volume and tumor weight were significantly inhibited in the group in which hSATII RNA expression was suppressed compared with the control group. This indicates that inhibition of hSATII RNA expression in stromal cells that induce cell senescence leads to inhibition of tumor growth.
[0153] The inventors of the present invention used DNA-FISH to detect the hSATII DNA region during the process of inducing cell senescence in TIG-3 cells by subculture, and found that the hSATII DNA region was relaxed before the expression of hSATII RNA ( Fig. 12A ). In addition, DNA-FISH was performed using the probe of sequence number 12, but any sequence can be used as long as it can detect the hSATIIDNA region. In addition, the chromatin accessibility of the hSATIIDNA region was analyzed based on DNaseI sequencing data of multiple cancer cell lines. As a result, the chromatin accessibility in cancer cells was significantly increased compared with normal fibroblasts ( Fig. 12B ).
[0154] Next, we analyzed whether the hSAT DNA region was open in tumor tissue. Using breast cancer patient specimens, we performed scATAC-seq ( Fig. 12C )、DNA FISH( Fig.12D ) analyzed the hSAT DNA region. scATAC-seq analysis was performed on breast cancer types (triple negative breast cancer: TNBC, luminal breast cancer: Luminal), and the results showed that the hSAT DNA region was open, that is, there was a possibility of active transcription. In addition, in luminal breast cancer, the relaxation of the hSAT DNA region was shown to be related to age, indicating a correlation with cell aging ( Fig. 12C ). In addition, DNA-FISH analysis showed that in breast cancer patient tissues, the hSAT DNA region was relaxed in breast cancer cells compared to normal breast epithelium, and in CAFs compared to normal fibroblasts ( Fig.12D ). In addition, clustering and analysis of each cell type showed that in patients with breast cancer cells with relatively closed hSATII regions, hSATIIDNA regions were open in stromal vascular endothelial cells and CAFs. Based on these results, it is possible that treatment targeting hSATIIDNA in stromal cells may be effective ( Fig.12E ).
[0155] According to the above results, by reducing the hSATII RNA expression as non-translated RNA in the centromere region, it is possible to treat cell aging and the cancer that follows it, and then prevent recurrence. As shown above, with hSATII RNA expression as a target, the material that suppresses its expression can become a new cancer treatment drug. That is, by using the medicament that suppresses hSATII RNA expression, the aging interstitial cells of cancer cells and secretion SASP factors can be removed. Specifically, as shown above, by the nucleic acid drugs of siRNA, LNA, etc., hSATII RNA can be reduced. For example, the siRNA shown in sequence numbers 1 and 2 can efficiently consume hSATII RNA, so it is useful. In addition, it is not limited to this, and LNA or siRNA can also be newly designed to use. In addition, it is also possible to screen for compounds that are targeted with hSATII RNA expression or stability and activity (specifically, inhibition of binding with CTCF, etc.).
[0156] Whether the disease is caused by cell senescence can be confirmed by examining the expression of hSATII RNA. For example, if the primer set shown by sequence numbers 4 and 5 is used, hSATII RNA expression can be confirmed by qPCR. hSATII RNA expression can also be evaluated by RNA-ISH. hSATII RNA is also contained in extracellular vesicles such as exosomes, so the amount of hSATII RNA in extracellular vesicles can also be detected using body fluids such as blood, urine, and ascites. In addition, SASP factors whose expression is promoted by hSATII RNA expression can also be measured. For SASP factors, RNA expression can be measured, and the amount of protein or the amount secreted can also be measured by ELISA. The sample used can be a tissue at the disease site, such as a suspected cancer tissue collected by biopsy, or an extracellular vesicle from a body fluid. In addition, the reduction of CTCF expression can be examined. When the expression of hSATII RNA, the expression of SASP factors, and the expression of CTCF are reduced, the above-mentioned pharmaceutical composition for inhibiting hSATII RNA expression can be used for treatment. Prior to the expression of hSATII RNA, the hSATII DNA region relaxes and chromatin accessibility increases, and therefore, there is the possibility that cancer can be diagnosed early based on epigenomic analysis such as DNA-FISH analysis or ATAC sequencing analysis, or analysis using genomic DNA fragments in body fluids or extracellular vesicles.
[0157] In addition, compounds can also be screened using epigenomic changes such as hSATII RNA expression or activity inhibition, SASP factor expression inhibition, or CTCF expression increase, shrinkage of hSATII DNA region, or decreased chromatin accessibility as indicators. For example, by constructing a system using a FRET test, low molecular weight compounds can be screened with high sensitivity. Specifically, a system can be constructed in which hSATII RNA is bound to beads labeled with a fluorescent substance that serves as a donor, and CTCF is bound to beads labeled with a fluorescent substance that serves as an acceptor through a specific binding substance such as an antibody ( Fig.13 ). By adding a library compound and exciting it with a specific fluorescence wavelength, it can be determined whether hSATII RNA and CTCF are in a close state. Alternatively, senescent cells are cultured with candidate compounds. If hSATII RNA expression is inhibited, CTCF expression is increased, the hSATIIDNA region is shrunk, or chromatin accessibility is reduced due to the candidate compound, it can function as a therapeutic drug for diseases caused by cellular senescence. The inhibition of hSATII RNA expression or activity, the increase in CTCF expression, and the reduction or reduced accessibility of the hSATII region of genomic DNA can be analyzed using methods commonly used in the art. Senescent cells, as used above, can be used in the cell senescence induction method commonly used in this field, such as subculture, X-ray irradiation, and doxorubicin exposure. hSATII RNA and CTCF expression can be analyzed using well-known methods such as RT-qPCR. In addition, it can also be monitored by gene expression analysis or secretion of the SASP factor group.
[0158] As shown above, the relationship between the SASP induction mechanism through hSATII RNA and the survival of senescent cells and cancer cells was found. In senescent cells and cancer cells, the paracentromere region of the chromosome is open, and hSATII RNA, which is a non-translated RNA, is actively transcribed from this region. It is known that hSATII RNA binds to CTCF, which plays an important role in maintaining the chromosome structure, and by inhibiting its function, the chromosome interaction changes and the transcription of the inflammatory gene group is induced. In addition, by inhibiting the expression of hSATII RNA in cancer cells or stromal senescent cells, cell death and proliferation arrest are induced, and cancer proliferation is suppressed, indicating that hSATII RNA can become a new target molecule for cancer treatment. By targeting hSATII RNA expressed in stromal cells or cancer cells that induce cell senescence, Seno-cancer therapy (senescent cancer therapy) that has both the senomorphic function of inhibiting the expression of the inflammatory SASP-related gene group and the senolytic function of selectively inducing cell death in senescent cells has the possibility of creating a new treatment method ( Fig.14 ).
Claims
1. A pharmaceutical composition, which is a therapeutic and / or preventive drug for cancer caused by cell senescence, wherein: Inhibit the expression of hSATII RNA or hinder its activity, and / or increase the expression of CTCF.
2. The pharmaceutical composition according to claim 1, wherein: The pharmaceutical composition is a nucleic acid drug that inhibits the expression of hSATII RNA or inhibits its activity, and / or increases the expression of CTCF.
3. The pharmaceutical composition according to claim 1 or 2, characterized in that: Targets both cancer cells and stromal cells.
4. The pharmaceutical composition according to claim 3, characterized in that: Used in combination with chemotherapy agents or radiation therapy.
5. A method for assisting in the detection of cancer, wherein: The hSATII RNA and / or CTCF expression in the sample is detected.
6. The inspection assisting method according to claim 5, characterized in that: When the hSATII RNA expression increases and / or the CTCF expression decreases, it is determined that the patient has cancer.
7. A method for assisting in the detection of cancer, wherein: Detect epigenomic changes in the hSATII DNA region in the sample.
8. The inspection assisting method according to claim 7, characterized in that: Assists in the detection of cancers caused by cellular senescence.
9. A method for screening a cancer therapeutic drug and / or preventive drug, which is a method for screening a cancer therapeutic drug and / or preventive drug caused by cell senescence, wherein the method is characterized by: Add candidate compounds to the culture medium of senescent cells. Candidate compounds are selected using at least one of hSATII RNA expression, hSATII RNA activity inhibition, CTCF expression increase, SASP factor expression decrease, hSATII DNA region shrinkage, and chromatin accessibility reduction as an indicator.
